Vivos Inc (RDGL)

[SC8]

Agreed. Very clear now, MK is pumping for another offering and appears he will be submitting an incomplete IDE application as part of that pump cuz he needs $ now. If so, at best RDGL will get a conditional IDE approval, meaning more meetings until all items are completed to FDA satisfaction. Hence why MK is not anticipating getting to human trials this year. There are just to many incompleted items and cleary, MK needs $ now.

Haven't read all weekend comments yet. Not sure why some were expected a small market local CBS affiliate covering Moose's saga to impact volume or pps?

Moreover, Moose received the now public domain version, for which there are no barriers to generic entry now. There is no evidence MK's "improved" process patent offers any performance advantages vs. Moose's treatment, likewise for RDGL's patents pending.

Facts are facts.